Lori Friedman
Chief Tech/Sci/R&D Officer chez ORIC PHARMACEUTICALS, INC.
Profil
Lori Friedman is a Director at Project Scientist and NextRNA Therapeutics, Inc. She is also the Chief Scientific Officer at Oric Pharmaceuticals, Inc. Previously, she worked as an Independent Director at Jiya Acquisition Corp.
and as the Head-Translational Oncology at Genentech, Inc. Friedman holds a doctorate degree from the University of California, Berkeley.
Postes actifs de Lori Friedman
| Sociétés | Poste | Début |
|---|---|---|
| ORIC PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/07/2019 |
| Project Scientist | Director/Board Member | - |
NextRNA Therapeutics, Inc.
 NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | Director/Board Member | 26/09/2023 |
Anciens postes connus de Lori Friedman
| Sociétés | Poste | Fin |
|---|---|---|
| JIYA ACQUISITION CORP. | Director/Board Member | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Formation de Lori Friedman
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ORIC PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| Project Scientist | |
Jiya Acquisition Corp.
 Jiya Acquisition Corp. Financial ConglomeratesFinance Jiya Acquisition Corp. is a blank check company. The firm was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It focuses on identifying promising opportunities in the biopharmaceutical sector. The company was founded in August 2020 and is headquartered in Palo Alto, CA. | Finance |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | Health Technology |
